Cargando…

A simple and clinically applicable model to predict liver-related morbidity after hepatic resection for hepatocellular carcinoma

BACKGROUND & AIM: Hepatic resection is a treatment option for patients with hepatocellular carcinoma (HCC). However, factors associated with candidacy for resection and predictive of liver-related morbidity after resection for HCC remain unclear. This study aimed to assess candidacy for liver re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Jonggi, Kim, So-Hyun, Han, Seungbong, Lee, Danbi, Shim, Ju Hyun, Lim, Young-Suk, Lee, Han Chu, Chung, Young-Hwa, Lee, Yung Sang, Lee, Sung-Gyu, Kim, Ki-Hun, Kim, Kang Mo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643950/ https://www.ncbi.nlm.nih.gov/pubmed/33152023 http://dx.doi.org/10.1371/journal.pone.0241808

Ejemplares similares

Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma
por: Choi, Jonggi, et al.
Publicado: (2020)

Identification of hepatic steatosis in living liver donors by machine learning models
por: Lim, Jihye, et al.
Publicado: (2022)

Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion
por: Lee, Danbi, et al.
Publicado: (2018)

The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection
por: Na, Seong Kyun, et al.
Publicado: (2018)

Association between statin use and the prognosis of hepatocellular carcinoma after resection: a nationwide cohort study
por: Jeon, Dongsub, et al.
Publicado: (2023)

Development of machine learning-based clinical decision support system for hepatocellular carcinoma
por: Choi, Gwang Hyeon, et al.
Publicado: (2020)

The Korean Hepatitis C Virus Care Cascade in a Tertiary Institution: Current Status and Changes in Testing, Link to Care, and Treatment
por: Choi, Jonggi, et al.
Publicado: (2022)

Could HBx Protein Expression Affect Signal Pathway Inhibition by Gefitinib or Selumetinib, a MEK Inhibitor, in Hepatocellular Carcinoma Cell Lines?
por: Park, Yoon Kyung, et al.
Publicado: (2011)

Chronic hepatitis B infection and non-hepatocellular cancers: A hospital registry-based, case-control study
por: An, Jihyun, et al.
Publicado: (2018)

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma
por: Choi, Won‐Mook, et al.
Publicado: (2020)

Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation
por: Yoo, Seo Yeon, et al.
Publicado: (2022)

Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment
por: Jin, Sujin, et al.
Publicado: (2023)

Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients
por: Lee, Sumin, et al.
Publicado: (2022)

The role of muscle depletion and visceral adiposity in HCC patients aged 65 and over undergoing TACE
por: Lim, Jihye, et al.
Publicado: (2021)

Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion
por: An, Jihyun, et al.
Publicado: (2017)

Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study
por: Choi, Won-Mook, et al.
Publicado: (2020)

Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B
por: Choi, Won-Mook, et al.
Publicado: (2022)

Role of 15-hydroxyprostaglandin dehydrogenase down-regulation on the prognosis of hepatocellular carcinoma
por: Yang, Jee Eun, et al.
Publicado: (2014)

Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma
por: Ha, Yeonjung, et al.
Publicado: (2016)

Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial
por: Yoon, Sang Min, et al.
Publicado: (2020)

Alpha-fetoprotein normalization as a prognostic surrogate in small hepatocellular carcinoma after stereotactic body radiotherapy: a propensity score matching analysis
por: Jung, Jinhong, et al.
Publicado: (2015)

Fibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma
por: Lee, Hyo Jeong, et al.
Publicado: (2015)

Stereotactic Body Radiation Therapy as an Alternative Treatment for Small Hepatocellular Carcinoma
por: Yoon, Sang Min, et al.
Publicado: (2013)

Stereotactic body radiation therapy for elderly patients with small hepatocellular carcinoma: a retrospective observational study
por: Jang, Jeong Yun, et al.
Publicado: (2022)

Propensity Score Matching Analysis of Changes in Alpha-Fetoprotein Levels after Combined Radiotherapy and Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
por: Jeong, Yuri, et al.
Publicado: (2015)

Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis
por: Bang, Yeong Hak, et al.
Publicado: (2022)

Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis
por: Kim, Ha Il, et al.
Publicado: (2023)

Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial
por: An, Jihyun, et al.
Publicado: (2017)

Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno‐oncology: A network meta‐analysis of randomized sorafenib‐controlled trials
por: An, Jihyun, et al.
Publicado: (2022)

Hepatocellular Carcinoma in Korea: an Analysis of the 2015 Korean Nationwide Cancer Registry
por: Yoon, Jun Sik, et al.
Publicado: (2021)

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
por: Lee, Sung Won, et al.
Publicado: (2021)

No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients
por: Heo, Nae-Yun, et al.
Publicado: (2014)

Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center
por: Kim, Sung Eun, et al.
Publicado: (2011)

Novel Preoperative Nomogram for Prediction of Futile Resection in Patients Undergoing Exploration for Potentially Resectable Intrahepatic Cholangiocarcinoma
por: Nam, Kwangwoo, et al.
Publicado: (2017)

Long‐term outcomes of laparoscopic versus open liver resection for intrahepatic combined hepatocellular‐cholangiocarcinoma with propensity score matching
por: Lee, Seung Jae, et al.
Publicado: (2022)

Sarcopenia Predicts Prognosis in Patients with Newly Diagnosed Hepatocellular Carcinoma, Independent of Tumor Stage and Liver Function
por: Ha, Yeonjung, et al.
Publicado: (2018)

The efficacy of treatment for hepatocellular carcinoma in elderly patients
por: Lee, Han Ah, et al.
Publicado: (2023)

Relation of fibroblast growth factor receptor 2 expression to hepatocellular carcinoma recurrence after liver resection
por: Jun, Baek Gyu, et al.
Publicado: (2020)

Intrahepatic recurrence of single nodular hepatocellular carcinoma after surgical resection: an analysis by segmental distribution
por: Kim, Jin‐Min, et al.
Publicado: (2018)

The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma
por: An, Jihyun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_efu0ta1pr9mn9ovdgaceqbcudd